Improved differential diagnosis of focal liver disease using SonoVue with nonlinear scanning mode
li ping,d baowei,xu yu
DOI: https://doi.org/10.1016/S0301-5629(03)00743-9
IF: 3.694
2003-01-01
Ultrasound in Medicine & Biology
Abstract:Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions.Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others).Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection.Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use. Objective: The aim of this study was to evaluate the efficacy of a new ultrasound contrast agent, SonoVue, in diagnosis and differential diagnosis of liver lesions. Methods: Thirty-one patients with difficult differential diagnosis or highly suspected for liver lesions on CT, MRI, or conventional US were studied. A dose of 2.4 ml of SonoVue (Bracco, Italy) was infused intravenously within 30 sec. The enhancement level was monitored with a nonlinear scanning mode using an Acuson Sequoia-512 scanner with 6C-2, 4C-1 probes. The comparison examinations were performed with physical examination in all cases and with library examination in 16 patients before and after SonoVue injection. The histopathalogical diagnoses were obtained in 20 patients after SonoVue enhanced US examination. The other diagnoses were confirmed on CT, MRI, and DSA. Twenty patients had malignant liver lesions (16 hepatocellular carcinomas, 4 metastases), while 11 had benign lesions (4 hemangiomas, 2 focal nodular hyperplasias, 5 others). Results: 1) After SonoVue injection, the number of lesions without flow signal intralesions dropped from 15 to 2 with nonlinear scanning modes. 2) The positive diagnoses compared to the histopathalogical diagnoses increased after SonoVue in nonlinear scanning modes (p<0.05). 3) There was no difference in physical examination and library examinations before and after SonoVue injection. Conclusions: SonoVue is useful in visualizing tumor vessel and characterizing liver tumors. It is a safe, efficient ultrasound contrast agent and convenient for use.